Kevin L McMahon
โ† Back to proof points
Digital Clinical Development delivery engine

From zero to 54: building the clinical technology delivery engine inside Ultragenyx.

As the only person at Ultragenyx with the title Digital Clinical Development, Kevin built and led a global Innovation Lab spanning software engineering, QA, product, study management, logistics, and clinical operations support.

54 peopleBuilt from zero into a global delivery organization.
Hybrid agile/scrumOperated as a software development shop and clinical trial support engine.
Live operationsSupported third-party EDC, mobile app workflows, device logistics, and studies.

Built the organization

Built and led the Innovation Lab from zero to 54 people across software engineering, QA, product management, product ownership, test engineering, study management, device logistics, and clinical operations support.

Hybrid agile/scrum software shop

The Lab operated as a hybrid agile/scrum development organization, translating emerging clinical technology needs into working software, workflows, and delivery cadence.

Clinical trial delivery engine

The team supported internal clinical technology, third-party EDC, mobile app workflows, patient/site technology support, device-enabled studies, and live clinical operations.

Cross-functional accountability

The Lab brought together disciplines normally scattered across IT, clinical operations, vendors, product, QA, study teams, and logistics into one accountable delivery model.

Request access to selected supporting materials

Selected source documents, diagrams, presentations, and summaries may be available for appropriate professional discussions.

Connected to clinical development strategy

The Innovation Lab was not isolated from clinical development strategy. Kevin also represented technology feasibility through clinical development leadership forums and Protocol Development Teams, connecting endpoint strategy, operational risk, patient-centered UI/UX, wearables, and CGM feasibility to live delivery.